Replay available

Imunon, Inc. (IMNN) Q2 2025 Earnings Call

Imunon, Inc. (NASDAQ: IMNN) Q2 2025 earnings conference call, held 2025-08-05. Replay captured from the company's public earnings webcast.

Tue, August 5, 2025 at 11:00 AMendedReplay
Imunon, Inc. (IMNN) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Peter Vozzo

Investor Relations Representative, ICR Healthcare for Immunon

Dr. Stacey Lindborg

President and Chief Executive Officer

Dr. Douglas Pollard

Chief Medical Officer

Dr. Krishid Anwar

Chief Scientific Officer

Kimberly Graper

Interim Chief Financial Officer

Emily Bodnar

Analyst, HC Wainwright

Will Heidel

Analyst, Brookline Capital Markets

David Botts

Analyst, Zacks Small Cap Research

James Malloy

Analyst, Alliance Global Partners

Replay transcript excerpt

Good morning. My name is Dhawan and I will be your operator today. At this time, I would like to welcome you to Immunon's second quarter 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question and answer session. You may press star 1 on your phone to ask a question at that time. Please keep in mind, if you are using a speakerphone, you must release your mute function to allow the signal to reach our equipment. Again, that's star 1 to ask a question during the Q&A session. I would now like to turn the call over to Peter Vozzo of ICR Healthcare, Investor Relations Representative for Immunon. Please go ahead. Thank you, Darwin. Good morning, everyone, and welcome to Immunon's second quarter 2025 financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Immunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expects, anticipates, believes, or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from those such statements. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, August 5, 2025. Immunon undertakes no obligation to revise or update comments made during this call, except as required by law. With that said, I would like to turn the call over to Dr. Stacey Lindborg...

More from Imunon, Inc.